{
    "nctId": "NCT01380353",
    "briefTitle": "Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine",
    "officialTitle": "Pilot Study to Test Uniformity of Transdermal Drug Delivery to the Breast Using Diclofenac Epolamine as a Model",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Compare concentrations of diclofenac epolamine patch when applied to breast vs. abdomen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women between the ages of 18 and 80 years, undergoing total mastectomy for, with or without axillary surgery for diagnosis or prevention of breast cancer.\n* ECOG performance status less than 2.\n* Ability to understand and the willingness to sign a written informed consent.\n* Participants must have normal organ and marrow function\n\nExclusion Criteria:\n\n* Prior history of ipsilateral breast radiotherapy.\n* Pregnant women and those who will be actively breast-feeding in the preoperative period will be excluded.\n* Inability to discontinue aspirin or warfarin use during the period of participation.\n* Known allergy to diclofenac epolamine, or aspirin, diclofenac (Cataflam, Voltaren), or another non-steroidal anti-inflammatory drug (NSAID).\n* Renal failure",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}